Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 4, 2006, Pages 789-792

  Esposito, Silvano ^a   Noviello, Silvana ^a   D'Errico, Gioacchino ^a   Motta, Gaetano ^a   Passali, Desiderio ^b   Aimoni, Claudia ^c   Pilucchi, Stefano ^c   Fallani, Stefania ^d   Cassetta, Maria Iris ^d   Mazzei, Teresita ^d   Novelli, Andrea ^d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Fluoroquinolones; Otorhinolaryngology; Pharmacokinetics

Indexed keywords

MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CHRONIC TONSILLITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; POSTOPERATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICAL ANALYSIS; TONSIL; TONSILLECTOMY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA; QUINOLINES; RECURRENCE; TONSIL; TONSILLECTOMY; TONSILLITIS;

EID: 33645125817     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl050     Document Type: Article

References (10)

1. Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163-74.
2. Stass H, Dalhoff A, Kubitza D et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-5.
3. Wirtz M, Kleeff J, Swoboda S et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 5: 875-7.
4. Breilh D, Jougon J, Djabarouti S et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J Chemother 2003; 15: 558-62.
5. Dinis PB, Monteiro MC, MartinsMLet al. Sinus tissue concentration of moxifloxacin after a single oral dose. Ann Otol Rhinol Laryngol 2004; 113: 142-6.
6. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. J Antimicrob Chemother 1999; 43 Suppl B: 1-11.
7. Falser N, Dalhoff A, Wenta H. Ciprofloxacin concentrations in tonsils following single or multiple administrations. Infection 1998; 16 Suppl 1: 14-8.
8. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32, 101-19.
9. Neeman R, Keller N, Barzilai A et al. Prevalence of internalisation-associated gene, prtF1, among persisting group-A streptococcus strains isolated from asymptomatic carriers. Lancet 1998; 352: 1974-7.
10. Novielllo S, Ianniello F, Esposito S et al. In vitro susceptibility of different erythromycin-resistant phenotypes of Streptococcus pyogenes to moxifloxacin and other fluoroquinolones. Infez Med 2000; 1: 34-8.